Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NYSE:LH NASDAQ:MYGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$196.92+1.7%$195.00$164.65▼$213.50$21.43B0.59809,409 shs980,761 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$258.80+1.7%$260.89$241.81▼$293.72$20.86B0.9595,138 shs404,552 shsMYGNMyriad Genetics$4.66+3.6%$4.39$3.53▼$8.59$425.02M1.731.62 million shs1.27 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.66%-2.02%+0.86%+0.31%+9.56%EXASExact Sciences0.00%0.00%0.00%0.00%+99.68%LHLabcorp+1.68%-2.40%-0.60%-2.82%-0.85%MYGNMyriad Genetics+3.56%+9.65%+21.99%-0.43%-4.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$196.92+1.7%$195.00$164.65▼$213.50$21.43B0.59809,409 shs980,761 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$258.80+1.7%$260.89$241.81▼$293.72$20.86B0.9595,138 shs404,552 shsMYGNMyriad Genetics$4.66+3.6%$4.39$3.53▼$8.59$425.02M1.731.62 million shs1.27 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.66%-2.02%+0.86%+0.31%+9.56%EXASExact Sciences0.00%0.00%0.00%0.00%+99.68%LHLabcorp+1.68%-2.40%-0.60%-2.82%-0.85%MYGNMyriad Genetics+3.56%+9.65%+21.99%-0.43%-4.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$216.589.99% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideLHLabcorp 2.73Moderate Buy$308.0019.01% UpsideMYGNMyriad Genetics 2.00Hold$6.5039.48% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, LH, MYGN, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (B+)6/4/2026MYGNMyriad Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)5/18/2026MYGNMyriad Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026LHLabcorp Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)5/6/2026MYGNMyriad Genetics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.005/6/2026MYGNMyriad Genetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.505/4/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (B+)5/1/2026LHLabcorp Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$334.004/22/2026DGXQuest Diagnostics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$210.00 ➝ $220.004/22/2026DGXQuest Diagnostics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $230.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$11.04B1.98$15.43 per share12.76$64.78 per share3.04EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34LHLabcorp$13.95B1.52$25.25 per share10.25$103.98 per share2.49MYGNMyriad Genetics$824.50M0.53$3.92 per share1.19$3.95 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$992M$9.0521.7617.022.319.07%15.60%7.06%7/23/2026 (Estimated)EXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/ALHLabcorp$876.50M$11.2922.9213.391.786.66%16.29%7.62%7/23/2026 (Estimated)MYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)Latest EXAS, LH, MYGN, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million4/30/2026Q1 2026LHLabcorp$4.09$4.25+$0.16$3.35$3.51 billion$3.54 billion4/21/2026Q1 2026DGXQuest Diagnostics$2.37$2.50+$0.13$2.24$2.83 billion$2.90 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.441.75%+7.34%38.01%14 YearsEXASExact SciencesN/AN/AN/AN/AN/ALHLabcorp$2.881.11%N/A25.51%N/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ALatest EXAS, LH, MYGN, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/19/2026DGXQuest Diagnosticsquarterly$0.861.81%7/8/20267/8/20267/22/20264/9/2026LHLabcorpquarterly$0.721.11%5/29/20265/29/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.671.181.08EXASExact Sciences0.972.432.17LHLabcorp0.681.731.54MYGNMyriad Genetics0.362.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%LHLabcorp95.94%MYGNMyriad Genetics99.02%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.88%EXASExact Sciences1.20%LHLabcorp0.84%MYGNMyriad Genetics1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics57,000110.70 million109.72 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableLHLabcorp71,00082.00 million81.31 millionOptionableMYGNMyriad Genetics2,70094.45 million92.65 millionOptionableEXAS, LH, MYGN, and DGX HeadlinesRecent News About These CompaniesMyriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication2 hours ago | markets.businessinsider.comMyriad Genetics Announces Resignation of Board Member SkovronskyJune 23 at 9:31 AM | tipranks.comMyriad Genetics Expands Availability of Precise MRDâ„¢ for Colorectal, Renal and Breast Cancers, Supported by New PublicationJune 23 at 9:14 AM | globenewswire.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives $6.50 Average Target Price from AnalystsJune 15, 2026 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from AnalystsJune 10, 2026 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Director Rashmi Kumar Sells 15,000 SharesJune 10, 2026 | insidertrades.comShould You Add Myriad Genetics Stock to Your Portfolio Right Now?June 9, 2026 | zacks.com1 cash-burning stock with promising prospects and 2 facing headwindsJune 5, 2026 | msn.comMyriad Genetics Holds 2026 Annual Meeting and Approves PlansJune 4, 2026 | tipranks.comMyriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?June 4, 2026 | zacks.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026June 2, 2026 | zacks.comMyriad Genetics Names Raj Jampa as New Chief Technology OfficerJune 2, 2026 | globenewswire.comMyriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its StockMay 28, 2026 | zacks.comIs MYGN Stock a Buy at 0.4x Sales? What Investors Should WeighMay 28, 2026 | zacks.comMYGN Cancer Care Strategy: What's Driving 2026 Growth PlansMay 27, 2026 | zacks.comMyriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual MeetingMay 27, 2026 | globenewswire.comMyriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)May 26, 2026 | globenewswire.comDown 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)May 18, 2026 | zacks.comMyriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing AwarenessMay 15, 2026 | quiverquant.comQActress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeMay 15, 2026 | globenewswire.comMyriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 15, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026IREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026AI’s Biggest Bottleneck Could Make These 2 Stocks SoarBy Jeffrey Neal Johnson | May 28, 2026These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to StayBy Thomas Hughes | June 23, 2026EXAS, LH, MYGN, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$196.92 +3.34 (+1.73%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$197.18 +0.27 (+0.13%) As of 06/23/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Labcorp NYSE:LH$258.80 +4.37 (+1.72%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$257.55 -1.25 (-0.48%) As of 06/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Myriad Genetics NASDAQ:MYGN$4.66 +0.16 (+3.56%) As of 06/23/2026 03:57 PM EasternMyriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
